Want to join the conversation?
$NKTR said it published pre-clinical results for NKTR-214, an investigational CD122-biased immune-stimulatory cytokine for the treatment of cancer in Clinical Cancer Research. The new paper documents durable anti-tumor efficacy, safety and immune mechanism of action of NKTR-214 in multiple tumor models.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?